Sophia Genetics Sa · NASDAQ:SOPH
Sophia Genetics Sa — Investor Presentation (August 2023)
21 slides from Sophia Genetics Sa's investor presentation, Aug 14, 2023
Slide 1: Democratizing Data-Driven Medicine
Democratizing Data - Driven Medicine Ross Muken Chief Financial Officer & Chief Operating Officer August 15, 2023
Slide 2: Cautionary Notices
Cautionary Notices This presentation contains statements that constitute forward - looking statements . All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy,
Slide 3: Snapshot of SOPHiA Genetics
Snapshot of SOPHiA Genetics The information on this slide is as of 06/30/2023. 3 © SOPHiA GENETICS 2023
Slide 4: The Emergence of the Cloud and AI have transformed countless industries
The Emergence of the Cloud and AI have transformed countless of industries Financial Services Human Resources IT Security Supply Chain Retail BUT, He a l t h c a r e is lagging 4 © SOPHiA GENETICS 2023
Slide 5: Healthcare Data is Complex, Siloed and Diverse
Healthcare Data is Complex, Siloed and Diverse 5 © SOPHiA GENETICS 2023
Slide 6: Creating Network Effects in Healthcare is Difficult
Creating Network Effects in Healthcare is Difficult given non - standardized methods and sensitive data 6 © SOPHiA GENETICS 2023
Slide 7: Cancer and Rare Diseases
Cancer >25 Million New Cancer Cases per Year 1 7 1. by 2040, 2 . https:// www.rarediseasesinternational.org/ Rare Diseases ~5% of the global population suffers from a Rare Disease 2 Significantly Important for Key Diseases driven by genomic alterations
Slide 8: New Data Modalities Bring Objectivity into human biology and diseases
New Data Modalities Bring Objectivity into human biology and diseases 8 © SOPHiA GENETICS 2023
Slide 9: Applying AI to Genomic Data
Applying AI to Genomic Data HRD example for PARP inhibitors 9 © SOPHiA GENETICS 2023
Slide 10: Applying AI to Multimodal Data
Applying AI to Multimodal Data NSCLC example for Immunotherapy 10 © SOPHiA GENETICS 2023
Slide 11: Our Ability to Deliver Healthcare Solutions
Our Ability to Deliver Healthcare Solutions Built on collective intelligence from our global network Discovery Apply benefits of proprietary AI/ ML to late - stage discovery phases 11 Development Comprehensive suite of applications backed by AI - based algorithms to aid in harmonization and reportin
Slide 12: Transforming Healthcare through Key Strategic Collaborations
Transforming Healthcare through Key Strategic Collaborations » Generate robust insights » Break data silos » Create a collective intelligence » Accelerate adoption of precision medicine 12
Slide 13: Growing with our Customer's Volume
© SOPHiA GENETICS 2023 Growing with our Customer’s Volume 13 Central Labs C o m p r e h e n s i v e Cancer Centers Specialty Labs University Hospitals In - House Sequencing Proprietary Algorithms and patented technologies 1 C o n s u m p t i o n based model Interpret Data Targeted Clinical Outcomes
Slide 14: A Look into a Customer's Expansion Journey
A Look into a Customer’s Expansion Journey as volume and the number of applications increase 14 © SOPHiA GENETICS 2023
Slide 15: Customer Growth Accelerates as they get Larger
Importantly, Customer Growth Accelerates as they get Larger Note: Based on recurring platform customers. FN 1: Represents CAGR of total tier revenue of customers with $100K+ in revenue and CAGR of total tier revenue of customers with $0 - $100K in revenue. 15 © SOPHiA GENETICS 2023
Slide 16: Key customer and financial metrics
750+ Total customers (1) 430+ Core Genomics customers (1) 1.4 million+ Genomic Profiles Analyzed (5) ~78,000+ Genomic profiles analyzed in 2Q 2023 (1) 30% - 35% 2023 constant currency ex COVID revenue growth guidance as of August 8, 2023 (2,4) 30% 2Q2023 constant currency ex COVID revenue growth (3)
Slide 17: Thank You
2®- SOPHIA Thank You ° e Sere
Slide 18: Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin
© SOPHiA GENETICS 2023 18 Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin for the Three Months Ended June 30, 2023 Amounts in USD thousands (unaudited) Three months ended June 30, 2023 Revenue $15,054 Cost of revenue ( 5 , 007 ) Gross profit $10,047 Amortization of capitalize
Slide 19: Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth
© SOPHiA GENETICS 2023 Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth and Constant Currency Revenue Growth Excluding COVID - 19 - Related Revenue 19 Source: SOPH Q2 2023 6 - K: https: //w ww .sec.gov/Archives/edgar/data/1840706/000184070623000022/sophiageneticssaex993q2202
Slide 20: Notes to the Reconciliation of IFRS to Adjusted Financials
© SOPHiA GENETICS 2023 20 Notes to the Reconciliation of IFRS to Adjusted Financials (1) Amortization of capitalized research and development expenses consists of software development costs amortized using the straight - line method over an estimated life of five years. These expenses do not have a
Slide 21: Consistent Growth in Analysis Volume
© SOPHiA GENETICS 2023 Consistent Growth in Analysis Volume accelerated momentum of analysis volume conducted on our platform in 1H 2023 So u r c e : Note: SOPH Q2 2023 6 - K https://www.sec.gov/ix?doc=/Archives/edgar/data/0001840706/000184070623000022/soph - 20230630.htm Includes analysis volume fr
SOPHiA GENETICS — Investor Presentation (August 2023) on 6ix